KEDI U.S. Dividend100 90% Participation + Daily Options Premium Index

Analysts forecast Procter & Gamble to release its Q4 2026 earnings report on August 4, 2026, forecasted. Low impact is estimated as the announcement date itself typically has minimal immediate price effect.

Quarterly dividend of $0.40 per share, ex-dividend date is June 12, 2026 scheduled

Medium importance is estimated due to the historical impact of quarterly earnings on stock volatility. Q1 2026 earnings release is scheduled.

Fourth quarter and full fiscal year 2026 earnings results for the period ending March 31, 2026 are scheduled.

The Annual Meeting of Shareholders is scheduled for May 21, 2026. Low importance estimated as annual meetings typically result in 1-5% price impact, scheduled.

Target is scheduled to release its Q1 2026 earnings on May 20, 2026. Analysts forecast EPS of approximately $1.34. This is a future event, and importance is estimated as High due to the potential for significant price movement based on results and updated guidance scheduled

Q1 2026 earnings release is scheduled for May 19, 2026, before the market opens. Analysts forecast EPS of around $3.42. High importance estimated as earnings releases typically trigger ≥10% price volatility, forecasted.

Ex-dividend date for the quarterly dividend of $1.14 per share declared on March 11, 2026. The dividend is payable on June 1, 2026 scheduled

The 2026 Annual Meeting of Shareowners on May 7, 2026, is of Low importance as annual meetings typically have minimal immediate price impact, scheduled.

MetLife is scheduled to release its Q1 2026 financial results after the market closes on May 6, 2026. Analysts forecast earnings of $2.20 per share. High importance is estimated due to potential market volatility following the announcement scheduled.

Q1 2026 earnings release is scheduled for after market close on May 5, 2026, with a conference call on May 6, 2026; Medium importance is estimated as this significant event provides a key update on company performance, scheduled.

First quarter 2026 earnings release scheduled for after market close on May 4, 2026; high impact expected due to proximity to the merger vote scheduled.

Williams Cos Inc. is scheduled to announce its first-quarter 2026 financial results after the market closes on Monday, May 4, 2026, with a conference call scheduled for May 5, 2026; significant price impact is expected.

High importance is assigned as quarterly earnings typically drive significant market volatility; ExxonMobil is scheduled to release its first quarter 2026 financial results on May 1, 2026, with a conference call to follow expected.

Chevron is scheduled to release its first-quarter 2026 earnings on May 1, 2026. Analysts forecast a year-over-year decline in quarterly EPS to around $0.92, but project a significant increase for the full-year 2026 earnings. Estimated 5% price impact based on historical earnings volatility. This is scheduled and forecasted.

Amgen is scheduled to report its first quarter 2026 financial results after the market close on April 30, 2026, followed by a conference call with management, scheduled. High importance is estimated due to typical volatility surrounding earnings releases.

First quarter 2026 earnings release and conference call scheduled for April 30, 2026. Analysts forecast a loss per share, reflecting charges from recent acquisitions, forecasted. High importance estimated as earnings typically drive significant price movement, scheduled.

Q1 2026 earnings scheduled for release before market open on April 30, 2026. Analysts forecast EPS around $2.36-$2.44. The release follows the disclosure of $13.7 billion in net outflows for the quarter, which is a key point of investor focus, expected.

Bristol-Myers Squibb is scheduled to release its Q1 2026 financial results on April 30, 2026. Analysts forecast an EPS of around $1.46 and revenue of $10.85 billion, a slight year-over-year decline forecasted. Medium importance is estimated as earnings releases typically cause 5-10% volatility.

Illinois Tool Works is scheduled to release its Q1 2026 financial results on April 30, 2026. Analysts forecast EPS of approximately $2.56 on revenue of $4.01 billion. This event is scheduled. Medium importance is estimated based on an expected price impact of over 5%.

The company is scheduled to release its Q1 2026 financial results before the market opens on April 30, 2026; price impact is estimated at Low (1-5%) as this is a routine announcement, scheduled.

ConocoPhillips is set to release Q1 2026 results on 2026-04-30 before market open; analysts forecast EPS of about $1.55-$1.65 and recent earnings-day moves near 2%, expected

Reported Q3 2026 adjusted EPS of $3.37 and revenue of $5.94 billion, beating analyst expectations, and raised full-year fiscal 2026 guidance.

A Citi analyst raised the price target on Exxon Mobil to $175, citing a 'structural re-engagement' from investors in the oil sector; Scotiabank also reportedly lifted its EPS forecasts for FY2026-2027 forecasted.

Xfinity Mobile, a Comcast brand, launched two new wireless plans, 'Mobile Plus' and 'Mobile Select', to attract and retain customers in its growing mobile segment. Low importance is estimated based on typical market response to product launches.

Reported Q2 2026 revenue of $10.6B (down 3% YoY) and non-GAAP EPS of $2.65, beating estimates. Issued Q3 revenue guidance of $9.2B-$10.0B and EPS of $2.10-$2.30, below consensus due to memory supply constraints. Stock fell ~4.5% in after-hours trading.

On April 28, 2026, the U.S. FDA's CDER proposed to withdraw the approval for Amgen's drug Tavneos due to effectiveness and safety concerns. High importance is estimated as drug withdrawals significantly impact revenue and reputation.

Received U.S. FDA clearance and CE Mark approval for its next-generation Ultreon 3.0 Software, an AI-powered coronary imaging platform.

Q1 2026 adjusted EPS of $0.87 missed analyst estimates by over 6%. Revenue of $303.0 million was in line with forecasts but down 10% sequentially. Assets under management (AUM) fell 4% during the quarter to $173.0 billion, driven by $3.1 billion in net client outflows.

Following strong Q1 earnings, William Blair upgraded the stock to 'Outperform' on April 28, 2026, and Robert W. Baird raised its price target on April 29, 2026 estimated

Reported Q1 2026 revenue of $12.5 billion (+12% YoY) and comparable EPS of $0.86 (+18% YoY), beating analyst estimates. The company raised its full-year 2026 comparable EPS growth guidance to 8-9%.

Reported Q3 FY2026 results on 2026-04-28 with sales of $20.52 billion (+4.7% YoY) and adjusted EPS of $0.94, missing analyst estimates of $0.95. Net earnings declined 15.2% YoY. Medium importance estimated due to the earnings miss.

UPS announced Q1 2026 results on April 28, 2026, with revenue of $21.2 billion and adjusted EPS of $1.07, beating analyst estimates; however, the stock fell following the announcement due to concerns about rising fuel costs and a cautious outlook.

On April 28, 2026, the FDA announced Amgen's participation in a new proof-of-concept pilot for real-time clinical trials (RTCT) for Imdelltra. Low importance is estimated as this is a procedural pilot program.

Declared a quarterly dividend of $0.77 per share. The ex-dividend date is May 15, 2026, and the dividend is payable on May 29, 2026.

Mondelez reported Q1 2026 results on April 28, 2026, with revenue of $10.08 billion and EPS of $0.67 beating estimates and reaffirmed FY26 guidance; price impact estimated at ≥1% due to the earnings beat.

On April 28, 2026, MetLife announced a 4.4% increase in its quarterly common stock dividend to $0.5925 per share.

State Street announced its intention to launch a tokenized fund servicing capability from Luxembourg by the end of 2026 to support digitally native fund structures. Estimated price impact of 1-5% due to strategic expansion expected.

The Board of Directors approved a quarterly dividend of $0.525 per share on April 28, 2026, a 5% increase from the prior year's quarterly dividend; the ex-dividend date is June 12, 2026.

On April 28, 2026, Watsco announced a definitive agreement to acquire Jackson Supply Company ($230M annual sales). The price impact is estimated to be Low (4% of revenue), with the transaction closure in Q2 2026 expected.

Reported Q1 2026 results on April 28, 2026, with revenue of $1.53 billion (flat year-over-year) and diluted EPS of $1.87, beating analyst estimates but declining 3% from the prior year. A Low price impact is estimated as the earnings beat was offset by the year-over-year decline, with this outcome expected.

Released Q1 2026 earnings on 2026-04-27, reporting EPS of $0.46 which beat analyst estimates of ~$0.40. The company reported its first year-over-year revenue growth in several years and provided strong Q2 2026 guidance, forecasting EPS of $0.67-$0.75, well above consensus. The news led to a stock price surge of over 40%.

KeyBanc analysts upgraded MSC Industrial Direct to Overweight from Sector Weight with a $117 price target following meetings with CEO Martina McIsaac; forecasted.

Announced the appointment of Troy Lahr as CFO (effective 2026-05-04) and Kristine Martin Anderson as President (effective 2026-05-01) on 2026-04-27.

Filed an amended preliminary prospectus with the SEC for a T. Rowe Price Active Crypto ETF, indicating progress towards launching a new product in the digital asset space.

Procter & Gamble reported Q3 fiscal 2026 earnings on April 24, 2026. Core EPS of $1.59 beat estimates, and net sales rose 7% to $21.2 billion, with organic sales up 3%. The company maintained its fiscal 2026 guidance.

On 2026-04-24, shareholders approved the 2026 Incentive Stock Program and Kevin Conroy was appointed to the Board of Directors, increasing the board size from twelve to thirteen members.

Procter & Gamble announced a 3% quarterly dividend increase to $1.0885 per share. The ex-dividend date was April 24, 2026. This marks the 70th consecutive year of dividend increases.